Answers are grounded in this paper and cite their sources.
Examines how side chain structure and carbonyl group affect immunostimulatory effects in saponin adjuvants, suggesting key modifications for enhanced activity.
VSA-1 and VSA-2 are recently developed semisynthetic saponin immunostimulants derived from natural Momordica saponins (MS) I and II, respectively, through the incorporation of a linear dodecyl or benzyl undecanoate side chain. In this study, a series of novel MS derivatives with systematically varied side-chain lengths and steric bulk were synthesized. Immunological evaluation revealed that for MS I derivatives, adjuvant activity increased with side-chain elongation from C8 to C12 but declined upon further extension to C16. Enhancement of side-chain bulk, achieved by substituting the linear primary amide with a secondary amide, resulted in diminished adjuvant activity. In the case of MS II derivatives, either elongation or shortening of the side chain relative to –(CH2)10COOBn led to loss of immunostimulatory function, as evidenced by reduced IgG1 and IgG2a production. Furthermore, for both VSA-1 and VSA-2, reduction of the C23 carbonyl group to a primary hydroxyl group completely abolished the adjuvant activity.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: